Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Moody Tiger is an international activewear brand established in 2018, focusing on functional and fashionable athleisurewear for children aged 4 to 14 years. The company specializes in developing high-tech fabrics that ensure comfort and quality, catering to the needs of active children. By combining style with practicality, Moody Tiger aims to provide a range of fashion-forward activewear options that appeal to both children and their parents.
Neuro3 Therapeutics
Seed Round in 2021
Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
P&R Measurement Technology Co., Ltd., established in 2011 and based in Zhuhai, China, specializes in the research, development, and application of advanced measurement and control technology. The company provides testing and automation solutions across various sectors, including motors, household appliances, consumer electronics, and energy power. With over 300 independent intellectual property rights, P&R Measurement has earned recognition as a national high-tech enterprise and has received multiple certifications, including ISO9001:2015. The firm focuses on engineering signal processing, acoustic and vibration testing, and structural analysis, offering custom and semi-custom testing equipment and consulting services. P&R Measurement also collaborates with universities and research institutions to enhance its technological capabilities. It operates subsidiaries in multiple locations, including Guangzhou, Suzhou, Hong Kong, and the United States, and has developed comprehensive solutions that are widely acknowledged by industry clients, contributing to its reputation in the testing and automation landscape.
ZSHK Laboratories
Series A in 2021
ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
HashQuark is a provider of staking and blockchain infrastructure services, specializing in the Proof of Stake (PoS) and Delegated Proof of Stake (DPoS) ecosystems. Founded in 2018 and based in Grand Cayman, the company offers a range of services including staking for institutions, individuals, and market professionals, as well as a Staking Cloud that enables token holders to securely store their tokens and earn staking rewards. HashQuark supports all mainstream PoS blockchains and has completed global server deployment, ensuring secure and stable operations for its clients. The company's focus is on providing efficient node management and fostering investment opportunities for both individual and institutional investors within the blockchain space.
Fingo is an online shopping platform for customers to buy products and share products with their friends. The platform incorporates social business models in Malaysia to connect and create customers. Fingo leverages on major social platforms where every member who signs up will be treated as a VIP and gain access to a wide selection of quality goods and suppliers from Tmall and Taobao, besides opening up new entrepreneurial opportunities via a members-reward system, allowing people get goods at a cheaper price but also earn through membership.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
Hangzhou INXX Fashion Co., Ltd. is a high fashion clothing brand based in Hangzhou, China, specializing in the retail of apparel and accessories through online platforms. The company focuses on delivering contemporary fashion items, catering to a modern consumer base that values style and convenience. By leveraging the internet for its sales, INXX aims to reach a broader audience and adapt to the evolving retail landscape.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
P&R Measurement Technology Co., Ltd., established in 2011 and based in Zhuhai, China, specializes in the research, development, and application of advanced measurement and control technology. The company provides testing and automation solutions across various sectors, including motors, household appliances, consumer electronics, and energy power. With over 300 independent intellectual property rights, P&R Measurement has earned recognition as a national high-tech enterprise and has received multiple certifications, including ISO9001:2015. The firm focuses on engineering signal processing, acoustic and vibration testing, and structural analysis, offering custom and semi-custom testing equipment and consulting services. P&R Measurement also collaborates with universities and research institutions to enhance its technological capabilities. It operates subsidiaries in multiple locations, including Guangzhou, Suzhou, Hong Kong, and the United States, and has developed comprehensive solutions that are widely acknowledged by industry clients, contributing to its reputation in the testing and automation landscape.
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
Finern Automation (Shanghai) Co., Ltd. specializes in manufacturing testing equipment for assembly lines, focusing on the automotive, consumer electronics, and new energy sectors. Established in 2011 and headquartered in Shanghai, the company operates three research and manufacturing centers in Shanghai, Shenzhen, and Wuhan, and maintains agencies in Hong Kong, the United States, and France. Finern provides a range of solutions, including assembly testing for automotive electronics such as motor assembly lines, electronic control units, and radar systems. In the consumer electronics domain, it develops automatic testing equipment for devices like air conditioner remote controls and optical modules. Additionally, the company offers assembly test lines for new energy applications, including lithium battery modules and 18650 batteries. Through its comprehensive services, Finern aims to enhance efficiency and effectiveness in advanced manufacturing processes.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
ConvenientPower HK Limited specializes in the design and development of wireless power applications tailored for mobile electronics users. The company offers wireless QI charging pads compatible with QI-certified receiver devices, available through retail outlets. Founded in 2006 and located in Shatin, Hong Kong, ConvenientPower HK has established strategic alliances with notable corporations, including Philips & Lite-On Digital Solutions Corp and ON Semiconductor Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.